Polyethylene furanoate market was valued at USD 38.3 million in 2025 and is projected to reach USD 78.2 million by 2035, registering a CAGR of 7.5 percent over the forecast period from 2026 to 2035. The PEF market is gaining traction as material certification for recycling compatibility increases confidence among converters, brand owners, and regulators. Recent endorsements and approvals in key markets confirm that PEF can be integrated into existing polyethylene terephthalate (PET) recycling streams without disruption, reducing barriers to commercial uptake and supporting sustainable packaging goals. These developments enable PEF to function not only as a standalone monolayer polymer but also as a barrier layer in multilayer PET bottles, aligning with circular economy objectives and reducing end?of?life waste concerns. 

Payment gateway market was estimated at $25.7 billion in 2025 and is expected to grow to $69.9 billion by 2035, registering a CAGR of 10.7% over the forecast period from 2026 to 2035. The surge in digital wallet usage is emerging as a central driver of growth in the global payment gateway market, fundamentally reshaping how consumers and merchants transact. According to the Worldpay Global Payments Report 2024, digital wallets delivered approximately $13.9 trillion in global transaction value in 2023, accounting for half of all e?commerce payments and 30% of point?of?sale consumer spend, and are projected to exceed $25 trillion by 2027 across online and in?store channels, highlighting their rising dominance in payment behavior. 

Overactive Bladder (OAB) therapeutics market was valued at $3.53 billion in 2025 and is projected to reach $4.86 billion by 2035, expanding at a CAGR of 3.4% over the forecast period from 2026 to 2035. The growing prevalence of Overactive Bladder (OAB) globally is a principal driver of demand for therapeutics, directly expanding the addressable patient population for both anticholinergic agents and beta-3 adrenoreceptor agonists. A rigorous meta-analysis incorporating more than 610,000 participants estimates the global prevalence of OAB at around 20%, indicating that a substantial share of adults experience symptoms requiring clinical management. Over the past two decades, prevalence has climbed from roughly 18.1% to 23.9%, reflecting demographic shifts and increasing risk factor burdens such as aging and obesity.

The optical spectrum analyzer market was valued at $480.2 million in 2025 and is projected to reach $822.9 million by 2035, expanding at a CAGR of 5.7% over the forecast period from 2026 to 2035. The growth of the global optical spectrum analyzer market is increasingly driven by the rapid expansion of fiber?optic infrastructure and high?speed optical communication deployment. As broadband infrastructure evolves to support 5G backhaul, cloud services, and data center interconnects, service providers and equipment manufacturers require more precise spectral measurement and troubleshooting tools, positioning optical spectrum analyzers as essential test?and?measurement equipment. High?quality, gigabit?class broadband and fiber?to?the?home upgrades are prioritised in both developed and emerging economies, strengthening demand for advanced optical characterization. 

Opioid induced constipation (OIC) drug market was valued at $953.2 million in 2025 and is projected to reach $1,463.9 million by 2035, growing at a CAGR of 4.5% during the forecast period from 2026 to 2035. The market is being driven by the increasing clinical recognition of OIC as a significant adverse effect of opioid therapy, especially in populations with chronic pain or cancer. As prescribing of opioids persists for pain management, clinicians are more frequently identifying and documenting constipation directly linked to opioid use, which in turn increases demand for targeted therapeutic interventions. This trend has expanded the role of peripherally acting mu?opioid receptor antagonists (PAMORAs) and other OIC?specific agents in treatment protocols, creating clearer pathways for product adoption and reimbursement.

Intravenous (IV) iron drugs market was valued at $2.82 billion in 2025 and is projected to reach $5.38 billion by 2035, registering a CAGR of 6.7% over the forecast period from 2026 to 2035. The market is experiencing significant growth driven by the high and persistent prevalence of iron deficiency and anemia globally, which increases clinical demand for effective therapeutic interventions. Iron deficiency remains the most common nutritional deficiency globally, affecting roughly one in four individuals and contributing substantially to anemia cases that require medical management beyond oral supplementation. IV iron therapies are increasingly used in settings where oral iron is ineffective, poorly tolerated, or too slow to correct severe deficiencies, such as chronic kidney disease and oncology?associated anemia.

The IBS-C drug market was valued at $2.30 billion in 2025 and is projected to reach $3.08 billion by 2035, registering a CAGR of 3.1% over the forecast period from 2026 to 2035. Recent epidemiological research indicates that IBS with constipation (IBS?C) represents a substantial portion of diagnosed IBS cases globally, supporting strong demand for targeted therapies in the IBS?C drug market. A comprehensive meta?analysis using the latest Rome IV criteria found that IBS?C accounted for approximately 34.2% of all IBS cases, reflecting a significant patient population requiring ongoing pharmacological intervention.

The HF acid globe valves market was valued at $460.2 million in 2025 and is projected to reach $909.5 million by 2035, expanding at a CAGR of 7.1% over the forecast period from 2026 to 2035. Refinery safety and regulatory scrutiny surrounding hydrofluoric acid (HF) use in alkylation units has become a major driver for the HF acid globe valves market, as operators seek valves with enhanced containment and fugitive-emission control. Renewed legislative attention, including proposed US federal action to prohibit HF use following concerns about the potential for mass casualty events from HF releases, has highlighted the need for advanced process safety systems. This trend pushes refiners to adopt globe valves engineered for higher reliability and corrosion resistance to support stringent operational protocols and reduce the likelihood of accidental releases.

Guidewires market was estimated at $1.50 billion in 2025 and is expected to reach $2.60 billion by 2035, reflecting a CAGR of 5.8% over the forecast period from 2026 to 2035. Recent product approvals and exclusive distribution agreements are directly strengthening momentum in the peripheral guidewires market. Regulatory clearances enable immediate commercialization of new guidewire technologies, while distribution partnerships expand geographic reach and procedural access within established interventional networks. Together, these developments shorten the path from innovation to clinical use and support faster uptake across hospitals and specialty interventional centres. The focus on longer-length guidewires, transradial access compatibility, and solutions for complex occlusions reflects evolving procedural needs in peripheral arterial and venous interventions.

The furniture market was estimated at $530.2 billion in 2025 and is forecast to reach $793.1 billion by 2035, expanding at a CAGR of 4.2% over the 2026–2035 period. The global furniture market is being shaped by expanding consumption and sustained trade flows in 2024–2025. Across residential and commercial end uses, furniture continues to circulate widely in international commerce and household purchasing. Official customs and trade datasets show that furniture exports from major producing regions remain substantial, reflecting consistent production output and international demand. Movement of furniture goods between economies, including shipments from the European Union, the US, and China, supports broad market activity and underscores furniture’s role as a traded manufactured product.